Enveric Biosciences, Inc. ENVB · Stock Open Enveric Biosciences, Inc. in new tab
Enveric Biosciences, Inc. Analysis (ENVB)
Is Enveric Biosciences, Inc. a good investment? Enveric Biosciences, Inc. (ENVB) is currently trading at 1.56 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.00. This relatively low multiple may signal that Enveric Biosciences, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Enveric Biosciences, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -1.41.
Investor FAQ
Does Enveric Biosciences, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Enveric Biosciences, Inc.?
Enveric Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -12.18.
Company Profile
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
| Year | Total Dividends |
|---|---|
| ▸2008 |
0.02 USD
|
| April 23, 2008 | 0.0210 |
| Split Date | Split Ratio to 1 |
|---|---|
| Dec. 17, 2008 | 1:10 |
| May 26, 2015 | 0.06 |
| Nov. 25, 2019 | 1:25 |
| Dec. 31, 2020 | 1:4 |
| July 15, 2022 | 1:50 |
| Jan. 27, 2025 | 0.07 |
| Oct. 28, 2025 | 0.08 |
Community Discussion